Drug Trial Radar · NCT00816023
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
Last checked: Nov 20, 2026Latest source record: Aug 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
276
Actual
Start
Mar 2009
Primary completion
Dec 2009
Study completion Jan 2010
Sponsor
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Dec 31, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.
Conditions
- Bloodloss
- Surgical Procedures, Operative
Interventions
ecallantideDrug
infusion administered IV over the duration of the surgical procedure
placeboDrug
solution for IV infusion over the duration of the surgical\>\> procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Volume of Packed Red Blood Cells Transfused at 12 Hours Post SurgeryTime frame: Start of surgery up to 12 hours after the end of surgery
Locations
29 sites in 2 countries. Site status is shown where the registry gives one.
Cardio-Thoracic Surgeons PC
Birmingham, Alabama
Drug Research and Analysis Corporation
Montgomery, Alabama
University of Colorado - Denver
Aurora, Colorado
Pepin Heart Hospital & Kiran Patel Research Institute
Tampa, Florida
Indiana Ohio Heart
Fort Wayne, Indiana
University of Kentucky
Lexington, Kentucky
Massachusetts General Hospital
Boston, Massachusetts
Caritas St. Elizabeth's Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
MCVI - Covenant Medical Center
Saginaw, Michigan
MCVI - St. Mary's of Michigan
Saginaw, Michigan
Mayo Clinic
Rochester, Minnesota
St. Luke's - Roosevelt Hospital Center
New York, New York
Weill Medical College of Cornell University
New York, New York
Duke University Medical Center
Durham, North Carolina
Integris Baptist Medical Center
Oklahoma City, Oklahoma
East Tennessee Cardiovascular Surgery Group
Knoxville, Tennessee
Texas Heart Institute
Houston, Texas
Sentara Heart Hospital
Norfolk, Virginia
Virginia Commonwealth University
Richmond, Virginia
Charleston Area Medical Center (CAMC)
Charleston, West Virginia
Foothills Medical Centre
Calgary, Alberta, Canada
St. Boniface General Hospital
Winnipeg, Manitoba, Canada
New Brunswick Heart Centre
Saint John, New Brunswick, Canada
Hamilton Health Sciences
Hamilton, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
Institut Universitaire de Cardiologie et de Pneumologie de Quebec (Hospital Laval)
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.